Fierce Pharma September 10, 2024
AbbVie’s migraine drug Ubrelvy (ubrogepant) is slated to be the top-selling drug in the migraine space in 2033 across the seven bigger pharma markets as total spend across those countries are set to rake in $16.4 billion.
That’s according to new migraine market figures out by analysts at GlobalData. They see Ubrelvy hitting sales of $1.07 billion in 2033, primarily because it has one of the later patent expiry dates in what has become a large and highly competitive migraine market.
Drug treatments and preventive meds include the likes of AbbVie’s other migraine meds, Qulipta and Botox, as well as Pfizer’s Nurtec ODT, Lundbeck’s Vyepti, Eli Lilly’s Emgality and Reyvow, and Teva’s Ejovy. There are also a lot of older,...
Today's Sponsors
Today's Sponsor